A Study to Evaluate the Influence of Pulse Electromagnetic Field Therapy on Myocardial Ischemia

Overview

About this study

The purpose of this study is to determine the impact of pulse electromagnetic field (PEMF) therapy using the Bioboosti device (Biomobie Regenerative Medicine Company) and therapeutic protocol on cardiac ischemia in patients with coronary artery disease as quantified using an assessment of myocardial blood flow using 13N-ammonia myocardial perfusion positron emission tomography (PET) scanning to quantify blood flow during chemical induced stress.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age ≥ 18 years old.
  • Known cardiac ischemia, who are non revascularizable, or have not and will not be undergo coronary intervention for the duration of their participation in the study.
  • Evidence of ischemia from previous clinical tests (echo, nuclear, standard ECG from past 6 months).
  • Left Ventricular Ejection fraction > 40% by echo (evaluated last 3 months).
  • Able to complete a cardiopulmonary exercise test without significant non cardiac limitations, primarily orthopedic.
  • On guideline directed optimal therapy for stable ischemia.

Exclusion Criteria:

  • Anemia (< 7 mg/dl).
  • Low potassium (< 3 mmol/L).
  • Creatinine (> 5.0 mg/dl or < 0.6 mg/dl).
  • Unable to exercise due primarily to orthopedic limitation.
  • Severe lung disease.
  • Morbid obesity (BMI > 42).
  • Pregnant.
  • Breast feeding.
  • Significant arrhythmia (Vtach, Vfib, frequent PVCs, persistent afib, or 2nd or 3rd degree AV block).
  • Seizures.
  • Unstable angina.
  • Coronary spasm.
  • Recent MI (< 90 days).
  • Recent PTCA (<90 days).

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bruce Johnson, Ph.D.

Contact us for the latest status

Contact information:

Jesse Schwartz B.S.

(480) 301-6616

Schwartz.Jesse@mayo.edu

Rochester, Minn.

Mayo Clinic principal investigator

Bruce Johnson, Ph.D.

Contact us for the latest status

Contact information:

Bruce Johnson Ph.D.

(507) 284-4375

johnson.bruce@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20491778

Mayo Clinic Footer